Inozyme Pharma

Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The firm is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The firm also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).